Maharashtra FDA permanently cancels Pune-based pharma firm's license over six contaminated medicines, GMP lapses
The Maharashtra FDA has permanently revoked the manufacturing license of InduCare Pharma Pvt. Ltd. following the discovery of contaminated medicines and severe manufacturing violations. Inspections revealed fungal growth, insects, and larvae in several Ayurvedic products.
Why it matters
Ensures public health safety by removing substandard and dangerous medical products from the market.
The Maharashtra Food and Drug Administration (FDA) on Thursday (August 6, 2026) permanently cancelled the Ayurvedic medicine manufacturing license of Pune-based InduCare Pharma Pvt. Ltd. after six medicines failed quality tests, with some found contaminated with fungi, insects and larvae, and widespread Good Manufacturing Practice (GMP) violations.
This action was taken after the manufacturing facility was inspected twice. The inspection revealed incomplete manufacturing records, poor hygiene, inadequate quality-control systems and the omission of ingredients specified in approved Ayurvedic formulations, according to the press release. The FDA said these violated provisions of the Drugs and Cosmetics Act, 1940, Rules, 1945, and GMP requirements.
The company failed to provide a satisfactory explanation despite a show-cause notice, a hearing, and a joint inspection, it added.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in